Publications of the Division of Health Economics
Journals with external peer review
2023
P.D. Pham, M. Schlander, R. Eckford, K. Hernandez-Villafuerte, J. Ubels
Developing a Conceptual Framework for Socioeconomic Impact Research in European Cancer Patients: A 'Best-Fit' Framework Synthesis
The Patient - Patient-Centered Outcomes Research: published 27 June 2023.
DOI: 10.1007/s40271-023-00632-z
R. Schaefer, D. Hernandez, T. Baernighausen, P. Kolominsky-Rabas, M. Schlander:
The HTA-informed Decision-Making by GBA/IQWiG in Germany and NICE in England: The Role of Budget Impact.
Value Health, 2023: 26(7):1032-1044
DOI: 10.1016/j.jval.2023.02.018.
D. Hernandez, C.-Y. Cheng, K. Hernandez-Villafuerte, M. Schlander:
Survival and comorbidities in lung cancer patients: evidence from administrative claims data in Germany
Oncology Research, 2022: 30(4), 173-185.
DOI: 10.32604/or.2022.027262.
C.-Y. Cheng, S. Calderazzo, C. Schramm, M. Schlander
Modeling the natural history and screening effects for colorectal cancer using both adenoma and serrated neoplasia pathways: the development, calibration, and validation of a discrete event simulation model.
MDM Policy & Practice, 2023: 8(1), published 21 Jan 2023.
DOI: 10.1177/23814683221145701.
S. A. Khan, K. Hernandez-Villafuerte, D. Hernandez, M. Schlander:
Estimation of the stage-wise costs of breast cancer in Germany using a modeling approach.
Frontiers in Public Health, 2023: 10, published 6 Jan 2023.
DOI: 10.3389/fpubh.2022.946544.
2022
J. Schneider, D. Hernandez, CAESAR study group, M. Schlander, V. Arndt:
Out-of-pocket payments and loss of income among long-term breast cancer survivors in Germany: A multi-regional population-based study.
Journal of Cancer Survivorship, 2022: 1-21.
DOI: 10.1007/s11764-022-01293-x.
M. T. Muchadeyi, K. Hernandez-Villafuerte, M. Schlander:
Quality appraisal for systematic literature reviews of health state utility values: a descriptive analysis.
BMC Medical Research Methodology, 2022: 22 (1), 303.
DOI: 10.1186/s12874-022-01784-6.
V. Arndt, D. Hernandez, M. Schlander:
Einkommenseinbußen nach Krebs – Ergebnisse aus Deutschland.
Onkologie, 2022: 28 951-956.
DOI: 10.1007/s00761-022-01243-3.
D. Hernandez, F. Wagner, K. Hernandez-Villafuerte, M. Schlander:
Economic burden of pancreatic cancer in Europe: a literature review.
Journal of Gastrointestinal Cancer, published online ahead of print 2022 Apr 26.
DOI: 10.1007/s12029-022-00821-3.
M. Brougham, M. Schlander, H. Telser, S. Bakshi, O. Sola-Morales:
Use of the incremental cost effectiveness ratio for decision-making policies - what's the problem? A perspective paper.
Expert Review of Pharmacoeconomics & Outcomes Research, 2022: 22 (6) 913-918.
DOI: 10.1080/14737167.2022.2064847.
J. Ubels, K. Hernandez-Villafuerte, M. Schlander:
The value of freedom: a review of the current developments and conceptual issues in the measurement of capability.
Journal of Human Development and Capabilities, 2022: 23 (3) 327-353.
DOI: 10.1080/19452829.2022.2053506.
J. W. März, A. Molnar, S. Holm, M. Schlander:
The ethics of COVID-19 vaccine allocation: Don't forget the trade-offs!
Public Health Ethics, 2022: 15 (1) 41-50.
DOI: 10.1093/phe/phac001.
D. Moro, M. Schlander, H. Telser, O. Sola-Morales, M. D. Clark, A. Olaye, C. Camp, M. Jain, T. Butt, S. Bakshi:
Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis, and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2].
Expert Review or Pharmacoeconomics & Outcomes Research, 2022: 22 (4) 581-598.
DOI: 10.1080/14737167.2022.2014324.
R. D. Eckford, A. Gaisser, V. Arndt, M. Baumann, E. Kludt, K. Mehlis, J. Ubels, E. C. Winkler, S. Weg-Remers, M. Schlander:
The COVID-19 pandemic and cancer patients in Germany: impact on treatment, follow-up and psychological burden.
Frontiers in Public Health, published online 2022 Feb 9: Article 788598.
DOI: 10.3389/fpubh.2021.788598.
A. Gaisser, R. D. Eckford, V. Arndt, D. Doege, E. Kludt, J. Ubels, M. Schlander, S. Weg-Remers:
Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer].
Der Onkologe, 2022: 28 (3) 248-252.
DOI: 10.1007/s00761-022-01096-w.
M. S. Y. Thong, D. Doege, L. Weißer, L. Koch-Gallenkamp, H. Bertram, A. Eberle, B. Holleczek, A. Nennecke, A. Waldmann, S. R. Zeissig, R. Pritzkuleit, M. Schlander, H. Brenner, V. Arndt:
Health and life insurance-related problems in very long-term cancer survivors in Germany: a population-based study.
Journal of Cancer Research and Clinical Oncology, 2022: 148 (1) 155-162.
DOI: 10.1007/s00432-021-03825-x.
2021
J. W. März, S. Holm, M. Schlander:
Resource allocation in the Covid-19 health crisis: are Covid-19 preventive measures consistent with the Rule of Rescue?
Medicine, Health Care and Philosophy, 2021: 24 (4) 487-492.
DOI: 10.1007/s11019-021-10045-0.
R. Schaefer, D. Hernandez, L Selberg, M. Schlander:
Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?
Journal of Comparative Effectiveness Research, 2021: 10 (16) 1187-1195.
DOI: 10.2217/cer-2021-0047.
M. Schlander, K. Hernandez-Villafuerte, C. -Y. Cheng, J. Mestre-Ferrandiz, M. Baumann:
How much does it cost to research and develop a new drug? A systematic review and assessment.
Pharmacoeconomics, 2021: 39 (11) 1243-1269.
DOI: 10.1007/s40273-021-01065-y.
C. -Y. Cheng, T. Datzmann, D. Hernandez, J. Schmitt, M. Schlander:
Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.
International Journal of Cancer, 2021: 149 (10) 1744-1754.
DOI: 10.1002/ijc.33728.
A. Deibel, L. Deng, C. -Y. Cheng, M. Schlander, T. Ran, B. Lang, N. Krupka, N. Beerenwinkel, G. Rogler, R. Wiest, A. Sonnenberg, J. Poleszczuk, B. Misselwitz:
Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach.
Gastrointestinal Endoscopy, 2021: 94 (2) 379-390.e7.
DOI: https://doi.org/10.1016/j.gie.2021.02.013.
D. Hernandez, M. Schlander:
Income loss after a cancer diagnosis in Germany: An analysis based upon the socio-economic panel survey.
Cancer Medicine, 2021: 10 (11) 3726-3740.
DOI: 10.1002/cam4.3913.
S. A. Khan, K. V. Hernandez-Villafuerte, M. T. Muchadeyi, M. Schlander:
Cost-effectiveness of risk-based breast cancer screening: A systematic review.
International Journal of Cancer, 2021: 149 (4) 790-810.
DOI: 10.1002/ijc.33593.
2020
T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Cost of decentralized CAR T cell production in an academic non-profit setting.
International Journal of Cancer, 2020: 147 (12) 3438-3445.
DOI: 10.1002/ijc.33156.
M. -J. Linton, P. M. Mitchell, H. Al-Janabi, M. Schlander, J. Richardson, A. Iezzi, J. Ubels, J. Coast:
Comparing the German translation of the ICECAP-A capability wellbeing measure to the original English version: psychometric properties across healthy samples and seven health condition groups.
Applied Research in Quality of Life, 2020: 15 (3) 651-673.
DOI: 10.1007/s11482-018-9681-5.
J. M. Heard, C. Vrinten, M. Schlander, C. M. Bellettato, C. van Lingen, M. Scarpa; MetabERN collaboration group:
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network.
Orphanet Journal of Rare Diseases, 2020: 15 (1) 1-10.
DOI: 10.1186/s13023-019-1280-5.
2019
T. Ran, C. -Y. Cheng, B. Misselwitz, H. Brenner, J. Ubels, M. Schlander:
Cost–effectiveness of colorectal cancer screening strategies: A systematic review.
Clinical Gastroenterology and Hepatology, 2019: 17 (10) 1969-1981.
DOI: 10.1016/j.cgh.2019.01.014.
M. Wagner, D. Samaha, R. Casciano, M. Brougham, P. Abrishami, C. Petrie, B. Avouac, L. Mantovani, A. Sarría-Santamera, P. Kind, M. Schlander:
Moving towards accountability for reasonableness: A systematic exploration of the features of legitimate healthcare coverage decision-making processes using rare diseases and regenerative therapies as a case study.
International Journal of Health Policy and Management, 2019: 8 (7) 424-443.
DOI: 10.15171/ijhpm.2019.24.
R. Schaefer, M. Schlander:
Is the National Institute for Health and Care Excellence (NICE) in England more ´innovation-friendly´ than the Federal Joint Committee (GBA) in Germany?
Expert Review of Pharmacoeconomics & Outcomes Research, 2019: 19 (4) 453-462.
DOI: 10.1080/14737167.2019.1559732.
J. J. Caro, J. E. Brazier, J. Karnon, P. Kolominsky-Rabas, A. J. McGuire, E. Nord, M. Schlander:
Determining value in Health Technology Assessment: Stay the course or tack away?
PharmacoEconomics, 2019: 37 (3) 293-299.
DOI: 10.1007/s40273-018-0742-2.
J. Richardson, M. Schlander:
Health Technology Assessment (HTA) and economic evaluation: Efficiency or fairness first.
Journal of Market Access & Health Policy, 2019: 7 (1) 1557981.
DOI: 10.1080/20016689.2018.1557981.
V. Jantzer, M. Schlander, J. Haffner, P. Parzer, S. Trick, F. Resch, M. Kaess:
The cost incurred by victims of bullying from a societal perspective: Estimates based on a German online survey of adolescents.
European Child and Adolescent Psychiatry, 2019: 28 (4) 585-594.
DOI: 10.1007/s00787-018-1224-y.
2018
M. Schlander, C. -Y. Cheng, T. Ran:
The health economics of cancer screening in Germany: Which population-based interventions are cost-effective? [Gesundheitsökonomie der Krebsfrüherkennung in Deutschland: Welche Interventionen sind kosteneffektiv bei bevölkerungsweiter Umsetzung?]
Bundesgesundheitsblatt, 2018 61 (12) 1559-1568.
DOI: 10.1007/s00103-018-2839-3.
J. Espin, M. Schlander, B. Godman, P. Anderson, J. Mestre-Ferrandiz, I. Borget, A. Hutchings, S. Flostrand, A. Paranby, C. Jommi:
Projecting pharmaceutical expenditure in EU5 to 2021: Adjusting for the impact of discounts and rebates.
Applied Health Economics and Health Policy, 2018 16 (6) 803-817.
DOI: 10.1007/s40258-018-0419-1.
M. Schlander, C. M. Dintsios, A. Gandjour:
Budgetary Impact and Cost Drivers of Drugs for Rare and Ultrarare Diseases.
Value in Health, 2018: 21 (5): 525-531.
DOI: 10.1016/j.jval.2017.10.015.
K. Hernandez-Villafuerte, A. Fischer, N. R. Latimer:
Challenges and methodologies in using progression free survival as a surrogate for overall survival in oncology.
International Journal of Technology Assessment in Health Care, (2018) 34(3) 300-316.
DOI: 10.1017/S0266462318000338.
2017
G. Steigner, C. Doarn, M. Schütte, D. Matusiewicz, C. Thielscher:
Health applications for corporate health management.
Telemedicine and E-Health, 2017: 23 (5) 448-452.
DOI: 10.1089/tmj.2016.0162.
L. Annemans, S. Aymé, Y. Le Cam, K. Facey, P. Gunther, E. Nicod, M. Reni, J. -L. Roux, M. Schlander, D. Taylor, C. Tomino, J, Torrent-Farnell, S. Upadhyaya, A. Hutchings, L. Le Dez:
Recommendations from the European working group for value assessment and funding processes in rare diseases.
Orphanet Journal of Rare Diseases, 2017: 12 (1) 50.
DOI: 10.1186/s13023-017-0601-9.
K. Hernandez-Villafuerte, J. Sussex, E. Robin, S. Guthrie, S. Wooding:
Economies of scale and scope in publicly funded biomedical and health research: Evidence from the literature.
Health Research Policy and Systems, (2017) 15 (1) 3.
DOI: 10.1186/s12961-016-0167-3.
Non-refereed publications
2023
D. Hernandez, S.A. Khan, M. Schlander
Krankheitslast von Brustkrebs in Deutschland: Epidemiologie und Kosten
Forum, 2023: published 20 June 2023.
DOI: 10.1007/s12312-023-01216-6
M. Schlander:
High-quality healthcare pays off (English version)
Aufwendige Gesundheitsversorgung zahlt sich aus (German version)
Gesundheitsindustrie BW, 11.1.2023 online.
2022
D. Hernandez, T. Ran, K. Hernandez-Villafuerte, M. Schlander:
Krankheitslast von Darmkrebs in Deutschland: Epidemiologie und Kosten.
Forum, 2022: published 24 Nov 2022.
DOI: 10.1007/s12312-022-01154-9.
M. Schlander, J. Richardson:
QALYs in health resource usage decisions.
Health Affairs, 2022: 41 (4) 609-610.
DOI: 10.1377/hlthaff.2021.01926.
D. Hernandez, P. Giri, A. von Both, M. Schlander:
Krankheitslast von Lungenkrebs in Deutschland: Epidemiologie und Kosten [Lung cancer disease burden in Germany: epidemiology and costs].
Forum, 2022: 37, 387-404.
DOI: 10.1007/s12312-022-01123-2.
D. Hernandez, A. von Both, M. Schlander:
Krankheitslast von Prostatakrebs in Deutschland: Epidemiologie und Kosten [Disease burden of prostate cancer in Germany: epidemiology and costs].
Forum, 2022: 37 227-234.
DOI: 10.1007/s12312-022-01075-7.
D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:
Die Messung der Kosten von Krebserkrankungen in Deutschland. Teil 2 – Wirtschaftliche Belastung [Determining the cost of cancer in Germany. Part 2—economic burden].
Forum, 2022: 37 42-48.
DOI: 10.1007/s12312-021-01026-8.
A. Gaisser, R.D. Eckford, V. Arndt, D. Doege, E. Kluddt, J. Ubels, M. Schlander, S. Weg-Remers:
Fast zwei Jahre Coronapandemie aus der Perspektive von Krebsbetroffenen [Nearly two years of the coronavirus pandemic from the perspective of people affected by cancer].
Forum, 2022: 37 216–220.
DOI: 10.1007/s12312-022-01092-6.
2021
D. Hernandez, K. Hernandez-Villafuerte, M. Schlander:
Die Messung der Kosten von Krebserkrankungen in Deutschland: Teil 1 – Epiemiologie und Krankheitslast [Determining the cost of cancer in Germany. Part 1 – epidemiology and disease burden].
Forum, 2021: 36 406-410.
DOI: 10.1007/s12312-021-00988-z.
J. W. März, M. Schlander:
Not kennt kein Gebot? Die Rule of Rescue als Leitprinzip in der Covid-19-Pandemie.
AMOS International, 2021: 15 (3): 39-44.
J. Ubels:
Saving money, saving lives: Health economics as a guide to cost-effective decision making.
International Journal of Cardiology, 2021: (339) 130-131.
DOI: 10.1016/j.ijcard.2021.06.053.
J. Ubels:
The assessment of value in health economics: utility and capability.
Defining the Value of Medical Interventions: Normative and Empirical Challenges (E-Book), 2021: 69-81.
ISBN (Print): 978-3-17-038176-6.
M. Schlander:
HTA agencies need evidence-informed deliberative processes. Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe.
International Journal of Health Policy Management, 2021: 10 (3) 158-161.
DOI: 10.34172/ijhpm.2020.22.
T. Ran, S. B. Eichmüller, P. Schmidt, M. Schlander:
Reply to: Comments on "Cost of decentralized CAR T cell production in an academic non-profit setting"
International Journal of Cancer, 2021: 148 (2) 516-517.
DOI: 10.1002/ijc.33253.
2020
M. Schlander:
PRO ("patient-reported outcomes") und Lebensqualität in der Onkologie [Patient-reported outcomes (PRO) and quality of life in oncology].
Forum, 2020: (35) 382-390.
DOI: 10.1007/s12312-020-00841-9.
M. Schlander:
HTA agencies need evidence-informed deliberative processes. Comment on "Use of evidence-informed deliberative processes by health technology assessment agencies around the globe.
International Journal of Health Policy Management (2020): 10 (3) 158-161.
DOI: 10.34172/ijhpm.2020.22
M. Schlander:
Allen Patienten gerecht werden. Gedanken eines Gesundheitsökonomen zur COVID-19-Krise.
Frankfurter Allgemeine Zeitung FAZ, 2020 May 29: (24) 20.
2019
C. Thielscher,B. Krol, S. Heinemann, M. Schlander:
Ethical decomposition as a new method to analyse moral dilemma.
INFORMATIK 2019, Hrsg: David, Geihs, Lange, Stumme.
Lecture Notes in Informatics (LNI), Gesellschaft für Informatik, 2019. Bonn.
DOI: 10.18420/inf2019_07
M. Schlander:
The economic evaluation of health care interventions: Opportunities for cooperation between the Division of Health Economics at DKFZ & clinical researchers (at U of Heidelberg, NCT, DKTK).
Heidelberg, 2019, April 17.
2018
K. Hernandez-Villafuerte, B. Zamora, Y. Feng, D. Parkin, N. Devlin, A. Towse:
Exploring variations in the opportunity cost cost-effectiveness threshold by clinical area: Results from a feasibility study in England.
Office of Health Economics, 2018: OHE Research Paper 19/3.
M. Schlander, K. Hernandez-Villafuerte, C. Thielscher:
Cost of cancer in Germany [Kosten der Onkologie in Deutschland].
Forum, 2018: 33 (5) 330-337.
DOI: 10.1007/s12312-018-0481-5
K. Hernandez-Villafuerte, B. Zamora, A. Towse:
Issues surrounding the estimation of the opportunity cost of adopting a new health care technology: Areas for Further Research.
Office of Health Economics, 2018: OHE Research Paper 18/7.
A. Towse, K. Hernandez-Villafuerte, B. Shaw:
A critique of the paper “The estimated costs of production and potential prices for the World Health Organization Essential Medicines List”.
Office of Health Economics, 2018: OHE Consulting Report.
M. Schlander:
Was ist uns die Krebsversorgung wert?
360° Onkologie Krebs und Politik, 2018: 2 (5) 4.
M. Schlander:
Das Schreckgespenst der Kostenexplosion ist nicht gut begründet.
Frankfurter Allgemeine Zeitung, 2018 Apr13: V2.
H. Telser, B. Fischer, M. Schlander:
Knappe Ressourcen und unbegrenzte Wünsche.
Im Dialog - CSS Journal 1, 2018: 4-6.
M. Schlander, B. Fischer, H.Telser:
Mithilfe der Wissenschaft die Kosten bremsen.
Im Dialog - CSS Journal 1, 2018: 8-9.
2017
T. Penzel, I. Flindell, R. Höger, U. Krämer, M. Schlander, J. Vogt, H.-E. Wichmann:
Evaluierung der Forschung zur Wirkung von Fluglärm auf den Menschen.
Interdisziplinäres Schlafzentrum Charité, Universitätsmedizin Berlin, 2017.
C. Thielscher:
Was kann die Gesundheitswirtschaft von der Medizin lernen?
D. Matusiewicz, M. Muhrer-Schwaiger (eds.):
Neuvermessung der Gesundheitswirtschaft, Springer, 2017: 253-268.
DOI: 10.1007/978-3-658-12519-6_23
M. Schlander, O. Schwarz, G.-E. Trott:
Unanswered questions: ADHD in Germany: trends in diagnosis and pharmacotherapy [ADHS in Deutschland: Trends in Diagnose und medikamentöser Therapie].
Deutsches Ärzteblatt International 2017: 114 (25) 428-429.
DOI: 10.3238/arztebl.2017.0428a
M. Schlander:
Woran bemisst sich Effizienz im Gesundheitswesen? Zur Klärung fachwissenschaftlicher Begriffe und Kriterien.
Amos International, 2017: 11 (1) 22-31.
M. Schlander:
Gescheiterte Börsenfusion – oder "Whatever it takes".
Frankfurter Allgemeine Zeitung (FAZ), 2017 Apr 11: 6.